Navigation Links
Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
Date:9/8/2008

SAN FRANCISCO, Sept. 8 /PRNewswire/ -- Takeda San Francisco Inc. announced today that Gregory Landes, Ph.D., has joined the company as vice president of antibody research. Dr. Landes will be responsible for directing the discovery and preclinical development of therapeutic antibodies at Takeda's antibody IND engine and center of excellence for biologics.

"Greg brings over 25 years of experience in the biopharmaceutical industry and is a great addition to the Takeda San Francisco management team," said Mary Haak-Frendscho, Ph.D. president and chief scientific officer, Takeda San Francisco. "Greg's extensive experience covers key aspects of antibody drug discovery and development. He will play an important role as we expand Takeda's biologics R&D capabilities in order to realize our goals of advancing superior therapeutics to contribute to the health of individuals."

Dr. Landes previously has held executive positions with major biopharmaceutical companies, including Lexicon Pharmaceuticals, Abgenix, Inc. and Genzyme Corp, where he led antibody drug discovery, antibody development and functional genomics. He has authored more than 49 peer-reviewed publications and is co-inventor on 12 issued plus additional pending patents. He holds a BA in Chemistry and PhD in Biochemistry from the University of Kansas and was a post-doctoral scholar at UCLA.

About Takeda San Francisco

Takeda San Francisco was established in November 2007 and supports Takeda's therapeutic antibody research aiming to build antibody technology platforms based on technologies such as discovery and development of antibodies, enhancement of antibody activity and antibody-manufacturing in close collaboration with Takeda's other R&D organizations. Additional information about Takeda San Francisco is available at http://www.takedasf.com.

About Takeda

Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.


'/>"/>
SOURCE Takeda San Francisco Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
2. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
3. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
4. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
5. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
6. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
7. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
8. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
9. Codexis Appoints Singapore Laboratories Managing Director
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... YORK , May 2, 2016 ... announces that its technology partner Mannin Research Inc. will ... Ophthalmology (ARVO), which takes place from May 1-5, 2016 ... executives will be meeting with its vendors and research ... explore business development goals and other collaborative opportunities for ...
(Date:5/2/2016)... ... May 02, 2016 , ... F.E.E.D. Co., the Feline Environmental ... revolutionary, veterinarian-designed product for indoor cats. The NoBowl Feeding System replaces the bowl ... the way nature intended. NoBowls make cats happy and healthy. , Since being ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... in spinal surgical procedures, today announced the completion of a significant transaction and ... current and future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a ...
(Date:4/29/2016)... Diego, CA (PRWEB) , ... April 29, 2016 , ... ... Foundation (NSCF) to support the development of a patient-specific stem cell therapy for the ... in the lab of Dr. Jeanne Loring at The Scripps Research Institute in San ...
Breaking Biology Technology:
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
(Date:3/17/2016)... , March 17, 2016 ABI Research, ... forecasts the global biometrics market will reach more ... 118% increase from 2015. Consumer electronics, particularly smartphones, ... fingerprint sensors anticipated to reach two billion shipments ... Dimitrios Pavlakis , Research Analyst at ABI ...
(Date:3/14/2016)... , March 14, 2016 NXTD ) ... mobile commerce market, announces the airing of a new series ... the week of March 21 st .  The commercials will ... its popular Squawk on the Street show. --> ... the growing mobile commerce market, announces the airing of a ...
Breaking Biology News(10 mins):